Tandem Diabetes Care (Nasdaq:TNDM) has shared new findings supporting the use of its Control-IQ technology in type 1 diabetes ...
Tandem Diabetes Care, Inc. TNDM presented positive real-world data, showing immediate and continued benefits across a diverse group of people using the t:slim X2 insulin pump with the Control-IQ ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial ...
Helping toddlers manage their Type 1 diabetes—typically a difficult task, due to their constant growth and development, not to mention fussiness—may now be a bit easier. The FDA has expanded its ...
The FDA approved its first automatic insulin dosing system designed to deliver correction boluses as well as adjust background insulin levels to help prevent bouts of high and low blood sugar in ...
A greater proportion of patients with type 1 diabetes who used automated insulin delivery systems vs multiple daily injections achieved the Healthcare Effectiveness Data and Information Set (HEDIS) ...
Tandem Diabetes Care TNDM remained under pressure on Monday, after the company accounted for plans of a combined analysis of three trials of its Control-IQ technology. Tandem Diabetes Care’s margins ...
The US Food and Drug Administration (FDA) has cleared Tandem Diabetes Care’s Control-IQ+ technology, an automated insulin delivery algorithm, for use in individuals aged 18 and above with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results